Background: Streptococcus agalactiae (Group B Streptococcus, GBS) is a leading cause of meningitis, sepsis and pneumonia in neonates in the United States. GBS also causes invasive disease in older infants, pregnant women, children and young adults with underlying medical conditions, and older adults. Resistance to lincosamides in the absence of erythromycin resistance is rare in GBS, but has been previously reported in clinical isolates, both on its own or in combination with resistance to streptogramins A and pleuromutilins (L/LSA/LSAP phenotypes). Objectives: To retrospectively screen the Active Bacterial Core surveillance (ABCs) GBS isolate collection for these phenotypes in order to identify the causal genetic determinants and determine whether their frequency is increasing. Methods: Based on MIC data, 65 (0.31%) isolates susceptible to erythromycin (MIC ≤0.25 mg/L) and non-susceptible to clindamycin (MIC ≥0.5 mg/L) were identified among 21 186 GBS isolates. Genomic DNA was extracted and WGS was performed. The presence of 10 genes previously associated with LSA resistance was investigated by read mapping. Results: Forty-nine (75%) isolates carried the lsa (C) gene and expressed the LSAP phenotype, and 12 (18%) carried both the lnu (B) and lsa (E) genes and expressed the LSAP phenotype. The four remaining isolates were negative for all determinants investigated. Conclusions: While the overall observed frequency of these phenotypes among our GBS isolates was quite low (0.31%), this frequency has increased in recent years. To the best of our knowledge, this is the first time the LSAP phenotype has been reported among GBS isolates from the USA. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy 2017. This work is written by US Government employees and is in the public domain in the US.
Background: Streptococcus agalactiae (Group B Streptococcus, GBS) is a leading cause of meningitis, sepsis and pneumonia in neonates in the United States. GBS also causes invasive disease in older infants, pregnant women, children and young adults with underlying medical conditions, and older adults. Resistance to lincosamides in the absence of erythromycin resistance is rare in GBS, but has been previously reported in clinical isolates, both on its own or in combination with resistance to streptogramins A and pleuromutilins (L/LSA/LSAP phenotypes). Objectives: To retrospectively screen the Active Bacterial Core surveillance (ABCs) GBS isolate collection for these phenotypes in order to identify the causal genetic determinants and determine whether their frequency is increasing. Methods: Based on MIC data, 65 (0.31%) isolates susceptible to erythromycin (MIC ≤0.25 mg/L) and non-susceptible to clindamycin (MIC ≥0.5 mg/L) were identified among 21 186 GBS isolates. Genomic DNA was extracted and WGS was performed. The presence of 10 genes previously associated with LSA resistance was investigated by read mapping. Results: Forty-nine (75%) isolates carried the lsa (C) gene and expressed the LSAP phenotype, and 12 (18%) carried both the lnu (B) and lsa (E) genes and expressed the LSAP phenotype. The four remaining isolates were negative for all determinants investigated. Conclusions: While the overall observed frequency of these phenotypes among our GBS isolates was quite low (0.31%), this frequency has increased in recent years. To the best of our knowledge, this is the first time the LSAP phenotype has been reported among GBS isolates from the USA. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy 2017. This work is written by US Government employees and is in the public domain in the US.
Authors: M Almuzara; L Bonofiglio; R Cittadini; C Vera Ocampo; A Montilla; M Del Castillo; M S Ramirez; M Mollerach; C Vay Journal: J Clin Microbiol Date: 2013-09-18 Impact factor: 5.948
Authors: Sarah Wendlandt; Carmen Lozano; Kristina Kadlec; Elena Gómez-Sanz; Myriam Zarazaga; Carmen Torres; Stefan Schwarz Journal: J Antimicrob Chemother Date: 2012-10-09 Impact factor: 5.790
Authors: A Montilla; A Zavala; R Cáceres Cáceres; R Cittadini; C Vay; G Gutkind; A Famiglietti; L Bonofiglio; M Mollerach Journal: Antimicrob Agents Chemother Date: 2014-06-23 Impact factor: 5.191
Authors: A Martel; M Baele; L A Devriese; H Goossens; H J Wisselink; A Decostere; F Haesebrouck Journal: Vet Microbiol Date: 2001-11-26 Impact factor: 3.293
Authors: B Bozdogan; L Berrezouga; M S Kuo; D A Yurek; K A Farley; B J Stockman; R Leclercq Journal: Antimicrob Agents Chemother Date: 1999-04 Impact factor: 5.191
Authors: Shannon D Manning; A Cody Springman; Erica Lehotzky; Maggi A Lewis; Thomas S Whittam; H Dele Davies Journal: J Clin Microbiol Date: 2009-01-21 Impact factor: 5.948
Authors: John Y Bolukaoto; Charles M Monyama; Martina O Chukwu; Sebotse M Lekala; Maphoshane Nchabeleng; Motlatji R B Maloba; Rooyen T Mavenyengwa; Sogolo L Lebelo; Sam T Monokoane; Charles Tshepuwane; Sylvester R Moyo Journal: BMC Res Notes Date: 2015-08-20
Authors: Bhavjinder K Dhillon; Matthew R Laird; Julie A Shay; Geoffrey L Winsor; Raymond Lo; Fazmin Nizam; Sheldon K Pereira; Nicholas Waglechner; Andrew G McArthur; Morgan G I Langille; Fiona S L Brinkman Journal: Nucleic Acids Res Date: 2015-04-27 Impact factor: 16.971
Authors: Rodrigo E Mendes; Susanne Paukner; Timothy B Doyle; Steven P Gelone; Robert K Flamm; Helio S Sader Journal: Antimicrob Agents Chemother Date: 2019-03-27 Impact factor: 5.191
Authors: M Belén Cubria; Luis Alberto Vega; William C Shropshire; Misu A Sanson; Brittany J Shah; Shrijana Regmi; Marcia Rench; Carol J Baker; Anthony R Flores Journal: Antimicrob Agents Chemother Date: 2021-10-11 Impact factor: 5.938
Authors: Lesley McGee; Sopio Chochua; Zhongya Li; Saundra Mathis; Joy Rivers; Benjamin Metcalf; Alison Ryan; Nisha Alden; Monica M Farley; Lee H Harrison; Paula Snippes Vagnone; Ruth Lynfield; Chad Smelser; Alison Muse; Ann R Thomas; Stephanie Schrag; Bernard W Beall Journal: Clin Infect Dis Date: 2021-03-15 Impact factor: 9.079